June 3, 2026 — Medtronic has announced strategic investments in two privately held companies focused on the development of intracardiac echocardiography (ICE) catheter technologies. ICE catheters provide real-time, high-resolution imaging of the heart during electrophysiology (EP) procedures for cardiac arrhythmias such as atrial fibrillation (Afib). Medtronic intends to integrate ICE into the Affera mapping and ablation system to continue building on the differentiated value proposition of the Affera ecosystem.

June 2, 2026 — AccurKardia, Inc. has been granted US Patent No. 12,620,488 for the company's proprietary machine-learning-based system for identifying cardiac amyloidosis from a standard, routinely performed 12-lead ECG.


Venous thromboembolism (VTE), and pulmonary embolism (PE) in particular, are among the most complex and dangerous acute cardiovascular conditions. VTE is the number one cause of preventable death among hospital patients, affecting up to 900,000 Americans each year and taking up to 100,000 lives.1,2 PE represents the third leading cause of cardiovascular death and accounts for the majority of deaths from VTE.3 

May 28, 2026 — RWJBarnabas Health has earned Cardiac Catheterization Lab Accreditation from the American College of Cardiology (ACC) in recognition of the health system’s excellence and consistency in delivering heart care. 

May 28, 2026 — Coredio has announced that the U.S. Food and Drug Administration (FDA) has granted its Cardiac Performance Simulation Engine (CPSE) Breakthrough Device Designation and accepted the platform into the FDA’s Total Product Life Cycle Advisory Program (TAP). CPSE is a software-only platform designed to deliver catheterization-comparable hemodynamic assessment using consumer smartwatches and standard blood pressure cuffs in clinical and home settings under physician supervision.

May 20, 2026 — Medtronic has released the three-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international head-to-head comparative trial of transcatheter aortic valve replacement (TAVR).

In patients with aortic stenosis (AS) and a small aortic annulus, results showed all individual and composite hemodynamic measures continue to be superior at three years for Evolut TAVR compared to SAPIEN. The science was presented at EuroPCR 2026 in Paris, France.

May 26, 2026 — According to researchers in Europe, women are more likely to face delays in diagnosis of cardiovascular disease and, as a result, they are more likely to die or develop more serious illness. To address this in inequality, Europe needs dedicated women’s heart centers, according to a report published in the European Heart Journal1.

May 21, 2026 — Adagio Medical Holdings, a provider of catheter ablation technologies for treating cardiac arrhythmias, has submitted its Premarket Approval (PMA) application to the U.S. Food and Drug Administration for the vCLAS Ventricular Ablation System for treating drug-refractory, recurrent, sustained monomorphic ventricular tachycardia (VT) in patients with ischemic or non-ischemic structural heart disease.

May 21, 2026 — A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data.

May 10, 2026 — WhiteSwell has announced primary results from the DELTA-HF feasibility clinical trial evaluating the eLym System for acute decompensated heart failure (ADHF). The data were presented at the Heart Failure 2026 Congress in Barcelona and simultaneously published in the European Journal of Heart Failure.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now